Milestone Scientific Inc. Commences Sales of CompuFlo® Epidural Instruments and Disposables to University Hospital of Würzb...
February 23 2021 - 9:30AM
Milestone Scientific Inc. (NYSE American:MLSS), a
leading developer of computerized drug delivery instruments that
provides virtually painless and precise injections, today announced
that it has begun selling its CompuFlo® Epidural Instrument and
related disposables to the University Hospital of Würzburg, one of
the leading national hospitals in Germany.
Dr. Peter Kranke, Professor of Anesthesia in the
Department of Anesthesia and Critical Care, at the University
Hospital of Würzburg, Germany, and the Würzburg Medical School,
stated, “Based on the high accidental dural punctures with the loss
of resistance that Dawkins found1 and our own published results on
the CompuFlo2, we are impressed with Milestone Scientific’s
CompuFlo Epidural Instrument. Introduction of the CompuFlo is an
important step towards enhancing the safety of epidural analgesia
and anesthesia. Based on the latest literature, the incidence of
accidental dural puncture is considered high by modern standards,
which is attributable to the standard loss of resistance technique
used today. CompuFlo provides an attractive alternative as it
addresses 'false-positives' and subsequent suboptimal analgesia.
CompuFlo also holds significant potential given its ability to
reduce complication rates.”
Arjan Haverhals, President of Milestone
Scientific, commented, “We appreciate the decision of the
University of Wurzburg, in association with Dr. Kranke and his
team, to purchase our CompuFlo Epidural System. Dr. Kranke is a
premier anesthesiologist and key opinion leader in the area of safe
delivery of anesthesia and analgesia. We believe this initial order
by a leading European hospital and medical teaching institute is
further validation that our technology provides a level of safety
and efficiency not available for medical professionals using
conventional syringes. We look forward to further expanding our
global rollout strategy of the CompuFlo Epidural System and working
closely with other hospitals across Europe and North America.”
Leonard Osser, Interim CEO of Milestone
Scientific, stated, “This agreement illustrates the positive
response for our CompuFlo Epidural Instrument. In addition to
hiring more salespeople and expanding our sales funnel, advanced
trials are already underway that we believe will convert to
commercial orders. We are now aggressively accelerating our
commercialization efforts in both domestic and global markets as we
pursue our goal to become the new standard of care.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical
technology research and development company that patents, designs
and develops innovative diagnostic and therapeutic injection
technologies and instruments for medical, dental, cosmetic and
veterinary applications. Milestone's computer-controlled systems
are designed to make injections precise, efficient, and virtually
painless. Milestone’s proprietary DPS Dynamic Pressure Sensing
technology® is our technology platform that advances the
development of next-generation devices, regulating flow rate and
monitoring pressure from the tip of the needle, through platform
extensions for local anesthesia for subcutaneous drug delivery,
with specific applications for cosmetic botulinum toxin injections,
epidural space identification in regional anesthesia procedures and
intra-articular joint injections. For more information please visit
our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking
statements regarding the timing and financial impact of Milestone's
ability to implement its business plan, expected revenues, timing
of regulatory approvals and future success. These statements
involve a number of risks and uncertainties and are based on
assumptions involving judgments with respect to future economic,
competitive and market conditions, future business decisions and
regulatory developments, all of which are difficult or impossible
to predict accurately and many of which are beyond Milestone's
control. Some of the important factors that could cause actual
results to differ materially from those indicated by the
forward-looking statements are general economic conditions, failure
to achieve expected revenue growth, changes in our operating
expenses, adverse patent rulings, FDA or legal developments,
competitive pressures, changes in customer and market requirements
and standards, and the risk factors detailed from time to time in
Milestone's periodic filings with the Securities and Exchange
Commission, including without limitation, Milestone's Annual Report
for the year ended December 31, 2019. The forward-looking
statements in this press release are based upon management's
reasonable belief as of the date hereof. Milestone undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
Contact:David Waldman or Natalya
RudmanCrescendo Communications, LLCEmail: mlss@crescendo-ir.comTel:
212-671-1020
___________________________________1 Anaesthesia 2021, 76,
414–4162 Springer Medizin Verlag GmbH: September 20, 2019
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Sep 2023 to Sep 2024